BioSpace News Archive

A study published in the Journal of the American Medical Association on July 29 now shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.

Olorofim is in a Phase IIb study that focuses on rare and resistant life-threatening invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis and coccidioidomycosis.

Whether you’re an experienced professional in the field or just embarking on your new career, it’s time to look at your qualifications and career plans from an entirely different perspective.

Moderna signed a contract worth up to $1.525 billion with the U.S. government to supply 100 million doses of mRNA-1273, the company’s experimental COVID-19 vaccine.

Celleron Therapeutics signed a licensing agreement with Roche for the worldwide rights to cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.

Just-published research in Cell outlines a way to make even immunotherapy-resistant cancers treatable.

Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease.

Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.

A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively-impacted by COVID-19 are also the least represented in these clinical studies.

Laurel Fuqua, RN, MSN, executive VP and chief clinical officer at Monarch Medical Technologies, will advise diabetes care and education specialists on “Data Visualization Skills for Diabetes Population Health Management” as a speaker on opening day for the Association of Diabetes Care and Education Specialists (ADCES) virtual annual conference- ADCES20.